Gerardo Hernandez
Fortune : 201 264 $ au 31/05/2026
Fortune : 201 264 $ au 31/05/2026
Gerardo Hernandez is currently Chief Financial Officer & Treasurer at TransMedics Group, Inc. since 2024.
Formerly, Mr. Hernandez was VP-Finance & Head-Financial Planning & Analysis at Alnylam Pharmaceuticals, Inc. from 2020 to 2024.
Education includes an MBA from Escola de Administração de Empresas de São Paulo and an undergraduate degree from the University of Wisconsin La Crosse.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 2 995 ( 0,01% ) | 201 264 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| TRANSMEDICS GROUP, INC. | Directeur Financier/CFO | 02/12/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/09/2024 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Escola de Administração de Empresas de São Paulo
Escola de Administração de Empresas de São Paulo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Wisconsin La Crosse
University of Wisconsin La Crosse Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TransMedics Group, Inc.
TransMedics Group, Inc. Medical SpecialtiesHealth Technology Manufactures portable electromechanical medical devices for organ transplantation of end-stage organ failure patients | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national